Table 4.
Univariate analysis of patient characteristics associated with 30 day all-cause mortality
| Parameter | OR 95% CI | p-value |
|---|---|---|
| Age (years) | 1.02 (1.01–1.04) | 0.01 |
| Charlson comorbidity index | 1.20 (1.07–1.33) | 0.001 |
| Pitt bacteremia score | 1.32 (1.15–1.50) | < 0.0001 |
| APACHE II score | 0.99 (0.95–1.02) | 0.43 |
| CLABSI | 2.74 (1.21–6.22) | 0.02 |
| HAP/VAP | 2.31 (1.15–4.64) | 0.02 |
| Complicated UTI | 0.50 (0.22–1.12) | 0.09 |
| Complicated intra-abdominal infection | 0.37 (0.14–1.03) | 0.06 |
| Skin and soft tissue infection | 0.75 (0.26–2.17) | 0.60 |
| Joint/bone infection | < 0.001 (< 0.001–> 999.99) | 0.98 |
| Primary bacteremia (source unidentified) | 2.17 (0.75–6.30) | 0.15 |
| CRE bacteremia | 2.75 (1.45–5.21) | 0.002 |
| NDM | 1.49 (0.67–3.31) | 0.32 |
| OXA48 | 1.35 (0.68–2.71) | 0.39 |
| Received CAZ-AVI | 0.75 (0.40–1.40) | 0.37 |
| Cardiac disease | 1.69 (0.81–3.55) | 0.16 |
| Diabetes Mellitus | 2.02 (1.08–3.79) | 0.03 |
| Non-hematological malignancy | 1.30 (0.22–3.37) | 0.44 |
| Hematological malignancy | 0.86 (0.67–2.49) | 0.83 |
| Immunosuppressive medication | 1.10 (0.52–2.32) | 0.81 |
OR odds ratio, CI confidence interval